Title : The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.

Pub. Date : 2019 Sep

PMID : 31284074






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The current study tested the ability of low dose colchicine to reduce CRP levels at 30 days after an acute MI, a key marker of future outcome, and its safety and tolerability in this setting. Colchicine C-reactive protein Homo sapiens
2 RESULTS: At 30-day follow-up, 44% of patients treated with colchicine had a CRP level >=2 mg/L compared to 50% of those randomized to placebo (P = .35) and the median CRP in patients randomized to colchicine was 1.6 mg/L (interquartile range [IQR] 0.7-3.5) compared to 2.0 mg/L (IQR 0.9-4.0) in patients randomized to placebo (P = .11). Colchicine C-reactive protein Homo sapiens
3 RESULTS: At 30-day follow-up, 44% of patients treated with colchicine had a CRP level >=2 mg/L compared to 50% of those randomized to placebo (P = .35) and the median CRP in patients randomized to colchicine was 1.6 mg/L (interquartile range [IQR] 0.7-3.5) compared to 2.0 mg/L (IQR 0.9-4.0) in patients randomized to placebo (P = .11). Colchicine C-reactive protein Homo sapiens
4 The median absolute reduction in CRP levels was -4.3 mg/L (IQR -1.1 to -14.1) among colchicine treated patients and -3.3 mg/L (IQR -0.9 to -14.4, P = .44) in placebo treated patients. Colchicine C-reactive protein Homo sapiens